普洛藥業(000739.SZ)74個產品納入國家醫保目錄3個產品退出
格隆匯8月22日丨普洛藥業(000739.SZ)宣佈,近日,國家醫保局和人力資源社會保障部發布了《關於印發
<國家基本醫療保險、工傷保險和生育保險藥品目錄>
的通知》(醫保發【2019】46號)。公司及下屬公司產品在2019版國家醫保目錄中調整情況公告如下:公司產品納入目錄的品種有74個,未有新增進入目錄品種,退出目錄品種有3個。
國家基本醫療保險、工傷保險和生育保險藥品目錄>
公司及下屬子公司共有74個產品納入2019版國家醫保目錄,其中甲類37個,乙類37個,納入目錄的主要重點產品包括阿莫西林克拉維酸鉀膠囊、頭孢拉定膠囊、鹽酸金剛乙胺口服溶液、注射用阿奇黴素枸櫞酸二氫鈉、吲達帕胺片等。
本次退出2019版國家醫保目錄的產品共3個,包括烏苯美司膠囊,氧氟沙星片和三七膠囊。以上產品調出醫保目錄對公司經營業績的影響暫無法估計。
公司多數重點產品仍納入在2019版國家醫保目錄內,這將有助於這些產品進一步的市場推廣和銷售,長期會對公司的經營業績產生一定積極影響。公司目前主要在研品種均在2019版國家醫保目錄內。下一步,公司在加強產品銷售推廣力度的同時,還會進一步加大藥品的研發力度,豐富公司產品管線,實現公司原料藥製劑一體化的戰略目標。
本次退出2019版國家醫保目錄的三個品種,未來將由醫保支付轉為自費支付,可能會對公司的經營業績產生一定的負面影響,但因新版目錄的執行還需待時日,因此,短期內尚不會對公司的經營構成影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.